Effects of a Novel Glucokinase Activator, Dorzagliatin, on Glycemic Control and Glucose Fluctuation in Drug-Naïve Patients with Type 2 Diabetes Mellitus
Open Access
- 27 December 2023
- journal article
- research article
- Published by Wiley in International Journal of Endocrinology
- Vol. 2023, 1-9
Abstract
Aim. The prevalence rate of type 2 diabetes mellitus (T2DM) has been increasing and a large proportion of patients still do not achieve adequate or sustainable glycemic control on the basis of previous hypoglycemic treatment. In this present study, we explored whether dorzagliatin, a novel glucokinase activator (GKA), could improve glycemic control and lessen glucose fluctuation in drug-naïve patients with T2DM. Methods. A self-comparative observational study of 25 drug-naïve patients with T2DM (aged 1875years and HbA1c of 7.511.0) treated with dorzagliatin 75mg twice daily for 52weeks. Before and after dorzagliatin intervention, the serum levels of hemoglobin A1c (HbA1c), insulin, and C-peptide were measured repeatedly during fasting and after a mixed meal. The continuous glucose monitoring (CGM) device was also used to obtain 24-hour glucose profiles and assess the changes in glycemic variability parameters. Results. After 52weeks of treatment with dorzagliatin, a numerally greater reduction in HbA1c of 1.03 from the baseline was observed in patients with T2DM, accompanied by significant improvement in insulin resistance and insulin secretion. Moreover, the standard deviation of blood glucose (SDBG) and the mean amplitude of glycemic excursion (MAGE) derived from CGM data were significantly decreased after dorzagliatin therapy. The 24-h glucose variation profile showed that study patients had obviously lower mean glucose levels during the postprandial period from the baseline to week 52, an effect also demonstrated by the significant decrease in the incremental area under glucose concentration versus time curve for 2h (iAUC02h) after meals. Conclusions. This study suggests that dorzagliatin therapy could effectively improve glycemic control and glucose fluctuation in drug-naïve patients with T2DM.Keywords
Funding Information
- National Basic Research Program of China (2018YFC1314103, JSSCBS20211546)
- Jiangsu Provincial Double Innovation Doctor Program (2018YFC1314103, JSSCBS20211546)
This publication has 44 references indexed in Scilit:
- Dose‐ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2013
- Glycemic variability: Clinical implicationsIndian Journal of Endocrinology and Metabolism, 2013
- Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 DiabetesDiabetes Care, 2011
- Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA studyEuropean Heart Journal, 2011
- The importance of glycated haemoglobin (HbA1c) and postprandial glucose (PPG) control on cardiovascular outcomes in patients with type 2 diabetesDiabetes Research and Clinical Practice, 2010
- Allosteric Activators of Glucokinase: Potential Role in Diabetes TherapyScience, 2003
- Glucose 6-Phosphate Produced by Gluconeogenesis and by Glucokinase Is Equally Effective in Activating Hepatic Glycogen SynthaseJournal of Biological Chemistry, 2003
- Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-AmericansDiabetes, 1995
- Liver Glucokinase: Decreased Activity in Patients with Type II DiabetesHormone and Metabolic Research, 1995
- Understanding Oral Glucose Tolerance: Comparison of Glucose or Insulin Measurements During the Oral Glucose Tolerance Test with Specific Measurements of Insulin Resistance and Insulin SecretionDiabetic Medicine, 1994